Meningococcal Infections

6
Pipeline Programs
4
Companies
13
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
4
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
3100%
+ 4 programs with unclassified modality

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Novartis
NovartisBASEL, Switzerland
4 programs
1
3
MenACWY CRMPhase 31 trial
MenACWY-CRMPhase 31 trial
MenACWY-CRM + MMRVPhase 31 trial
NZ MenB OMV vaccinePhase 2Vaccine1 trial
Active Trials
NCT00774384Completed9Est. Nov 2011
NCT00450437Completed3,539Est. Jan 2008
NCT00616421Completed2,907Est. Oct 2009
+1 more trials
Sanofi
SanofiPARIS, France
1 program
1
MenACYW conjugate vaccinePhase 3Vaccine5 trials
Active Trials
NCT06647407Active Not Recruiting750Est. May 2027
NCT06284915Completed840Est. Nov 2025
NCT06128733Completed1,215Est. Aug 2025
+2 more trials
Walvax Biotechnology
Walvax BiotechnologyChina - Kunming
1 program
1
Meningococcal Group ACYW135 Conjugate VaccinePhase 1Vaccine1 trial
Active Trials
NCT04236960CompletedEst. Nov 2019
GSK
GSKLONDON, United Kingdom
1 program
4CMenbN/A1 trial
Active Trials
NCT02712177Completed4,535Est. Apr 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
SanofiMenACYW conjugate vaccine
SanofiMenACYW conjugate vaccine
SanofiMenACYW conjugate vaccine
SanofiMenACYW conjugate vaccine
SanofiMenACYW conjugate vaccine
NovartisMenACWY-CRM
NovartisMenACWY-CRM + MMRV
NovartisMenACWY CRM
NovartisNZ MenB OMV vaccine
SanofiMenACYW conjugate vaccine
SanofiMenACYW conjugate vaccine
Walvax BiotechnologyMeningococcal Group ACYW135 Conjugate Vaccine
GSK4CMenb

Clinical Trials (13)

Total enrollment: 20,986 patients across 13 trials

NCT06284915SanofiMenACYW conjugate vaccine

Study on Immunogenicity and Safety of a Meningococcal ACYW Conjugate Vaccine in Healthy Infants and Toddlers

Start: Mar 2024Est. completion: Nov 2025840 patients
Phase 3Completed
NCT03547271SanofiMenACYW conjugate vaccine

Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe

Start: Dec 2018Est. completion: May 20231,660 patients
Phase 3Completed
NCT03537508SanofiMenACYW conjugate vaccine

Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US

Start: Apr 2018Est. completion: Sep 20232,627 patients
Phase 3Completed
NCT03476135SanofiMenACYW conjugate vaccine

Immunogenicity and Safety of a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine in Children

Start: Feb 2018Est. completion: Sep 201891 patients
Phase 3Completed
NCT03205371SanofiMenACYW conjugate vaccine

Immunogenicity and Safety of a Meningococcal Conjugate Vaccine Given Concomitantly With Other Vaccines in Toddlers

Start: Nov 2016Est. completion: Jul 20181,183 patients
Phase 3Completed
NCT00616421NovartisMenACWY-CRM

Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children

Start: Mar 2008Est. completion: Oct 20092,907 patients
Phase 3Completed
NCT00626327NovartisMenACWY-CRM + MMRV

Safety and Immune Response of Novartis MenACWY-CRM Conjugate Vaccine When Given to Healthy Toddlers

Start: Feb 2008Est. completion: Oct 20101,630 patients
Phase 3Completed
NCT00450437NovartisMenACWY CRM

A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults

Start: Mar 2007Est. completion: Jan 20083,539 patients
Phase 3Completed
NCT00774384NovartisNZ MenB OMV vaccine

Regulation of Mucosal Immune Response to Systemic MenB Vaccine

Start: Sep 2009Est. completion: Nov 20119 patients
Phase 2Completed
NCT06647407SanofiMenACYW conjugate vaccine

Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants

Start: Nov 2024Est. completion: May 2027750 patients
Phase 1/2Active Not Recruiting
NCT06128733SanofiMenACYW conjugate vaccine

Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents

Start: Oct 2023Est. completion: Aug 20251,215 patients
Phase 1/2Completed
NCT04236960Walvax BiotechnologyMeningococcal Group ACYW135 Conjugate Vaccine

Safety Evaluation of Meningococcal Group ACYW135 Conjugate Vaccine in 2-month to 55 Years Old Population.

Start: Jul 2018Est. completion: Nov 2019
Phase 1Completed
NCT02712177GSK4CMenb

Bexsero™and Routine Infant Vaccines: Effect of Coadministration on the Safety of Immunization

Start: Aug 2008Est. completion: Apr 20194,535 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 late-stage (Phase 3) programs — potential near-term approvals
4 companies competing in this space